Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.
Key facts
- Who runs it
- Procare Health Iberia S.L.
- Where
- Spain19 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 164 people enrolled
- Started
- 25 Sept 2019
- Ended
- 30 Jun 2024
- Type of study
- Interventional, 4 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Papilocare vaginal gel
- Record updated
- 2 September 2026
Who can take part
- Age
- 30 years to 65 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Woman between the ages of 30 and 65 (both inclusive)
- Able to read and understand the Patient Information Sheet and the Informed Consent form
- Acceptance in the participation of the essay and signature of the Informed Consent form
- ASC-US or LSIL or AG-US cytological result (maximum 3 months prior to inclusion) with concordant colposcopic image (performed at the screening visit)
- High risk HPV positive by PCR performed at screening visit
- Is able, at the discretion of the researcher, to comply with the requirements of the trial and without hindrance to follow the instructions and assessments throughout it
Who cannot take part
- Clinically relevant immune system alterations, or any other autoimmune disease or in treatment with immunosuppressants
- Non-diagnosed abnormal genital hemorrhage (during the 6 months prior to the screening visit)
- Surgical cervical excision in the last year or total hysterectomy
- Previous history of gynecological cancer
- Participation in any other clinical trial at present or in the 4 weeks prior to the inclusion of the trial
- Any planned surgery that prevents the correct compliance with the guidelines
- Other symptomatic vulvovaginal infections
- Contraindications for the use of Papilocare® gel or known allergies to any of its components
- Women of childbearing age who do not use effective contraceptive methods, pregnant women, with suspicion of pregnancy or woman who are breastfeeding
- To had been vaccinated against HPV
- Use of vaginal contraceptives or other vaginal hormonal treatments
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV-HR. All the patients included in the study will be randomized (1:1:1:1) in 4 arms.
The 4 groups in the trial
- A - papilocare alternative days treatmentTreatment being tested
Arm A: scheme A (21 days / 1 cannula per day + 7 days rest) x 1 month + alternate days up to 6 months (except for menstruation days)
Treatment: Papilocare vaginal gel
- B - papilocare semiintensive treatmentTreatment being tested
Arm B: scheme B (21 days / 1 cannula per day + 7 days rest) x 3 months + alternate days up to 6 months (except menstruation days)
Treatment: Papilocare vaginal gel
- C - papilocare intensive treatmentTreatment being tested
Arm C: scheme C (21 days / 1 cannula per day + 7 days rest) x 6 months
Treatment: Papilocare vaginal gel
- D - standard of careNo study treatment, for comparison
Arm D: usual clinical practice - no treatment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Ensayo clínico Aleatorizado, Abierto, Paralelo, Controlado, multicéntrico, Para Explorar la Eficacia Del Gel Vaginal Papilocare® en la reparación de la Mucosa Cervical Con Lesiones Causadas Por Virus Papiloma Humano de Alto Riesgo
- Record updated
- 2 September 2026